Your browser doesn't support javascript.
loading
Dietary recommendations for dysbetalipoproteinemia: A need for better evidence.
Paquette, Martine; Blais, Chantal; Fortin, Andréanne; Bernard, Sophie; Baass, Alexis.
Afiliação
  • Paquette M; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.
  • Blais C; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.
  • Fortin A; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada.
  • Bernard S; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Medicine, Division of Endocrinology, University of Montreal, Montreal, Québec, Canada; Research Centre of the Centre Hospitalier Universitaire de Montréal (CRCHUM), Montreal, Québec, Can
  • Baass A; Genetic Dyslipidemias Clinic of the Montreal Clinical Research Institute, Montreal, Québec, Canada; Department of Medicine, Divisions of Experimental Medicine and Medical Biochemistry, McGill University, Montreal, Québec, Canada. Electronic address: alexis.baass@ircm.qc.ca.
J Clin Lipidol ; 17(4): 549-556, 2023.
Article em En | MEDLINE | ID: mdl-37268489
ABSTRACT
The increased risk of cardiovascular disease in patients with dysbetalipoproteinemia (DBL) is well documented and is associated with the dysfunctional metabolism of remnant lipoproteins. Although these patients are known to respond well to lipid-lowering medication including statins and fibrates, the best dietary approach to lower remnant lipoprotein accumulation and to prevent cardiovascular outcomes remain unclear. Indeed, current evidence is based on studies published mainly in the 1970s, which comprise small sample sizes and methodological limitations. This review aims to summarize nutritional studies performed in DBL patients to date and to discuss potential avenues in this field and future areas of research.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Hiperlipoproteinemia Tipo III Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Hiperlipoproteinemia Tipo III Idioma: En Ano de publicação: 2023 Tipo de documento: Article